Insmed Q2 2026 Earnings: BRINSUPRI Drives $425.5 Million in Revenue

Insmed (NASDAQ: INSM) reported Q2 2026 revenue of $425.5 million, up 296% from $107.4 million a year earlier, while diluted net loss narrowed to $0.06 per share from $1.70. BRINSUPRI supplied nearly all of the revenue increase and improved product margins, although a favorable contingent-consideration remeasurement also materially reduced the reported loss.

Core Financial Results

BRINSUPRI generated $309.2 million in its second full quarter of reported sales, accounting for approximately 73% of company revenue. ARIKAYCE contributed the remaining $116.3 million and continued to grow, particularly in international markets.

Higher revenue and a more favorable product mix lifted gross profit. At the same time, R&D and SG&A increased as Insmed invested in TPIP development and BRINSUPRI commercialization.

*Product gross profit and margin are calculated as revenue less cost of product revenue and exclude intangible-asset amortization.

Product and Regional Performance

BRINSUPRI was the main growth driver, with global revenue rising 49% from Q1 2026. The U.S. generated $308.6 million of its $309.2 million total, showing that the product’s current commercial base remains heavily concentrated in that market.

ARIKAYCE revenue increased 8%, led by 19% international growth compared with 2% growth in the U.S. The following table separates product and geographic trends without mixing sequential and year-over-year comparisons.

BRINSUPRI had no comparable revenue in Q2 2025. Its sequential growth was driven by continued expansion in the U.S. market, according to the company.

BRINSUPRI improved margins, while a valuation adjustment boosted reported profit

Cost of product revenue increased to $67.2 million from $28.1 million, but it fell to approximately 15.8% of revenue from 26.1%. Insmed attributed the lower cost ratio to BRINSUPRI, which has lower manufacturing costs than ARIKAYCE. This product mix was a central reason the approximate product gross margin increased to 84.2%.

The near elimination of the operating loss was not solely an operating improvement. Insmed recorded a $99.8 million reduction in expense from the change in fair value of contingent-consideration liabilities, compared with a $59.0 million expense in Q2 2025—a favorable year-over-year swing of approximately $158.8 million. This offset part of the higher recurring spending, including a 60% increase in SG&A related primarily to BRINSUPRI commercial activity and a 19% rise in R&D tied partly to TPIP development and higher personnel costs.

Balance Sheet and Planned Investment

Insmed ended June 2026 with $544.8 million in cash and cash equivalents and $615.5 million in marketable securities, for a combined total of approximately $1.2 billion. That was approximately $269.7 million below the combined $1.43 billion held at the end of 2025.

Accounts receivable increased to $215.3 million from $140.9 million as revenue expanded, while inventory rose to $142.4 million from $132.1 million. Long-term debt was $543.5 million, and the royalty-financing obligation was $159.8 million.

The company plans to continue investing in BRINSUPRI commercialization, ARIKAYCE regulatory and commercial work, four Phase 3 TPIP indications, INS1148, gene-therapy programs, INS1033 and preclinical research.

2026 Guidance

Insmed raised its full-year BRINSUPRI revenue outlook following the product’s 49% sequential growth. It maintained the existing ARIKAYCE range, indicating no change to its annual expectations for that product.

Separately, management increased its long-term peak revenue estimates to more than $7 billion for BRINSUPRI and more than $6 billion for TPIP, while retaining an estimate of more than $1 billion for ARIKAYCE. These are peak-sales estimates rather than 2026 guidance.

Management Commentary and Pipeline Milestones

Management attributed BRINSUPRI’s early commercial performance to U.S. patient and physician demand. The company continues to expect a Japanese regulatory decision for brensocatib in the second half of 2026, although it is evaluating how evolving U.S. policies could affect the timing of future international launches.

For ARIKAYCE, Insmed submitted a supplemental U.S. application in July 2026 seeking use in newly diagnosed patients with MAC lung disease and plans to review supporting data with Japanese regulators during the second half. TPIP’s Phase 3 PAH and PH-ILD trials are enrolling, with additional Phase 3 programs in PPF and IPF planned for the second half of 2026 and first half of 2027, respectively.

Recent Insider Transactions

Over the reported six-month period, insiders acquired 366,025 shares across 26 transactions and sold 387,809 shares across 30 transactions. The resulting net sale was 21,784 shares, equal to 1.90% of the approximately 1.12 million insider shares held.

The 10 most recent reported entries include several derivative-security exercises followed by sales. The records below describe the transactions without implying a view on the company’s prospects.

Risks Investors Should Monitor

• BRINSUPRI concentration: The product generated approximately 73% of quarterly revenue, almost entirely in the U.S. Maintaining launch momentum is therefore increasingly important to overall growth.
• Rising recurring expenses: R&D and SG&A both increased as Insmed expanded commercial and clinical activities. The favorable contingent-consideration adjustment makes the reported loss improvement stronger than the change in recurring expenses alone.
• Regulatory and clinical execution: Future growth plans depend partly on BRINSUPRI’s Japanese decision, ARIKAYCE label-expansion reviews and multiple Phase 3 TPIP programs.
• Funding intensity: Cash and marketable securities declined by approximately $269.7 million during the first half, while the company continues to fund a broad commercial and clinical-development agenda.
• International launch timing: Insmed said evolving U.S. policies could affect the timing of potential international BRINSUPRI launches.

Conclusion

Insmed’s Q2 2026 results show a major shift from a largely ARIKAYCE-based commercial business to one led by BRINSUPRI. The new product drove most of the revenue increase and improved product margins, while higher commercial and development spending—and the large effect of contingent-consideration accounting—remain important when assessing profitability. The next points to monitor are BRINSUPRI’s sales trajectory, execution against the raised guidance and progress on ARIKAYCE and TPIP regulatory and clinical milestones.